<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain><z:e sem="disease" ids="C0948380" disease_type="Neoplastic Process" abbrv="">Metastatic colorectal cancer</z:e> is the second leading cause of <z:e sem="disease" ids="C1306459,C0006826" disease_type="Neoplastic Process" abbrv="">cancer</z:e> <z:hpo ids='HP_0011420'>death</z:hpo> in the United States </plain></SENT>
<SENT sid="1" pm="."><plain>Since 1995, treatment regimens have included <z:chebi fb="0" ids="31348">capecitabine</z:chebi>, irinotecan, <z:chebi fb="0" ids="31941">oxaliplatin</z:chebi>, bevacizumab, cetuximab, panitumumab, aflibercept, and reforafenib </plain></SENT>
<SENT sid="2" pm="."><plain>These medications have doubled the median survival of patients and improved the 5-year survival from less than 1% to 20% </plain></SENT>
<SENT sid="3" pm="."><plain>Approximately 75% of patients stop first-line chemotherapy in clinical trials for reasons other than progressive disease and face the question of whether to consider "maintenance" chemotherapy or take a chemotherapy break </plain></SENT>
<SENT sid="4" pm="."><plain>In this challenging case, Drs </plain></SENT>
<SENT sid="5" pm="."><plain>DÃ­az-Rubio, Pietrantonio, and de Braud reflect on the data and offer their opinions </plain></SENT>
<SENT sid="6" pm="."><plain>If each of the nearly 40,000 patients in the U.S. who face this decision chooses bevacizumab, the total cost is approximately $240 million per dose ($6,000 per infusion) </plain></SENT>
<SENT sid="7" pm="."><plain>The importance of this question and the cost to society are enormous </plain></SENT>
</text></document>